Introduc tion Bone tissue is a metabolic ally ac tive organ whic h is c ontinuously remodelled. The regulation of bone resorption, bone formation and interac tions between different hormones and c ytokines in human osteoblasts is not c ompletely understood. Growth hormone ( GH) is important in determining final body height and for normal bone physiology. High levels of gluc oc ortic oids result in osteoporosis, while oestrogen has a protec tive effec t on bone mass. Interleukin-6 ( IL-6 ) and interleukin-1 ( IL-1 ) are two c ytokines whic h are believed to be of importanc e for the loc al regulation of bone remodeling. This report is a summary of my thesis in whic h I investigated the effec ts of GH, oestrogen and c ortisol and their interac tions with eac h other and with interleukins in vitro in primary isolated human osteoblast-like c ells 1 .
Bone Tissue and Bone Remodeling The skeleton has a protec tive role for vital organs; it ac ts as a supporting frame for musc les and c onnec tive tissue and is the important loc ation for haematopoiesis. It also serves as a reservoir of c alc ium and other ions, like phosphate and magnesium. There are two different kinds of bone: c ortic al and c anc ellous ( trabec ular) bone. Cortic al bone is c ompac t and found mostly in long bones as a shell, whereas c anc ellous bone c onsists of a network of bone trabec ulae and is found mostly in the vertebrae and pelvis. Canc ellous bone is more metabolic ac tive with a larger surfac e area and is, therefore, more susc eptible to bone resorption 2 .
Bone forming c ells, osteoblasts ( OBs) , are derived from mesenc hymal stroma prec ursor c ells in the bone marrow. The c ells ac tively sec rete the extrac ellular matrix on one side of the c ell3 . To qualify as an OB, c ells are required to display some part of the c harac teristic s that are typic al for OBs. These phenotypic al c harac teristic s inc lude: the synthesis of c ollagen type I, the expression of alkaline phosphatase ( ALP) ac tivity, the expression of osteoc alc in, intrac ellular c AMP stimulation by parathyroid hormone and the ability to mineralize the extrac ellular matrix, osteonec tin, osteopontin and vitamin D rec eptors 3 , 4 .
Several different isolation and c ulture methods have been used to study OBs in vitro, mainly c onfined to c hic ken, rabbit, and rodent tissue or transformed c ells. In the 1 9 8 0 s Crisp et al. 5 and Mac Donald et al. 6 reported new methods for isolating primary OBs from human c anc ellous bone, whic h was an important step towards understanding human bone physiology better. The c ells obtained by using these c ulture methods are not transformed and display osteoblastic phenotype. Today, two different methods are mainly ac c epted for the isolation of human osteoblast-like c ells ( OBs) ; with enzymatic digestion 7 or without enzymatic digestion treatment 5 , 6 of bone c hips.
The c ell responsible for the resorption of bone matrix is the osteoc last ( OC) . This is a large, multinuc leated c ell whic h is believed to be derived from haematopoietic stem c ells in the bone marrow. Osteoc lasts are asymmetric c ells, having a ruffled border region whic h is an area where ac tive resorption takes plac e 8 . The skeleton was for many years regarded as an inac tive tissue but today it is regarded as a metabolic ally ac tive and dynamic tissue. The c ontinuous removal of bone ( bone resorption) by OCs and the following synthesis of new bone matrix and its subsequent mineralization ( bone formation) by OBs is a proc ess c alled bone remodeling, see 1 when OBs or OB-derived c ells ( bone lining c ells) digest the unc alc ified osteoid and, thereby, expose the mineralized bone surfac e. Prec ursors of OCs then start to differentiate into mature OCs, whic h attac h to the bone surfac e and start to resorb bone. This bone resorption is followed by a reversal phase during whic h the OCs are replac ed by other c ells. Furthermore, pre-OBs proliferate and start to form new unmineralized bone matrix, referred to as osteoid, whic h is subsequently mineralized. This phase is then followed by a quiesc ent phase before a new bone remodeling c yc le starts again 2 , 9 .
The proc ess by whic h bone resorption is followed by bone formation is c alled c oupling and is ensures that the bone removed is replac ed by new bone. Thus, c oupling sec ures the balanc e between resorption and formation. Osteoporosis is a systemic metabolic bone disease where there is an imbalanc e in the remodelling c yc le. The definition of osteoporosis, ac c ording to the World Health Organization, is when the bone mineral density ( BMD) is > = 2 .5 standard deviations below peak bone mass ( the maximal bone mass) 1 1 . The c linic al c onsequenc es of osteoporosis are frac tures, mainly affec ting the spine, the hip and the forearm.
Growth H ormone Acts Directly on H uman Osteoblast-like Cells
It is well known that GH is important in determining longitudinal bone growth and for normal bone remodeling 1 who demonstrated func tional GH rec eptors on rat osteosarc oma c ells and on mouse OBs. The number of GH-binding sites was lower in human OBs ( approximately 2 0 0 0 ) than in rat osteosarc oma c ells ( 9 0 0 0 ) . The lower number of GH-binding sites in human OBs c ompared with rat osteosarc oma c ells may be due to the fac t that human OBs are a heterogeneous c ell population of primary c ells and/or might reflec t a spec ies differenc e. Furthermore, the high expression of GH-binding sites in rat osteosarc oma c ells may be a c onsequenc e of the transformed phenotype. As OBs express func tional GH rec eptors, GH c an ac t direc tly on bone. GH has been shown to inc rease GH rec eptor mRNA levels and GH-binding in rat epiphyseal c hondroc ytes 1 8 and in mouse OB c ells 1 7 .
GH is known to be anabolic for OBs and to stimulate the proliferation of c ultured OBs. Some studies, but not all, demonstrate that GH regulates the differentiation of c ultured OBs 1 9 , 2 0 , 2 1 , 2 2 . GH was found to inc rease the proliferation but not differentiation ( ALP ac tivity) of human OBs 1 5 . The lac k of effec t on ALP ac tivity may be due to the c ulture c onditions 2 3 . Another explanation c an be that human OBs are a heterogeneous c ell population, c onsisting of c ells at different stages of differentiation. There are, ac c ording to Stein et al. 2 4 , well established variations in the c ompetenc y of OBs to respond to different hormones throughout differentiation.
There are several signs that Insulin-like growth fac tor 1 ( IGF-1 ) is important in bone remodeling and that IGF-1 is a fac tor whic h is embedded in the bone matrix and c an ac t as a c oupling fac tor between bone formation and bone resorption 2 5 . We demonstrated 2 6 that human OBs express IGF-1 mRNA and this is similar to results obtained simultaneously by Okazaki et al. 2 7 . This finding shows that IGF-1 is loc ally produc ed by OBs.
The somatomedin hypothesis states that GH stimulates the produc tion of IGF-1 in the liver, and that the liverproduc ed IGF-1 then stimulates longitudinal bone growth in an endoc rine manner 2 8 . Another theory for the effec t of GH on longitudinal bone growth is the "dual effec tor theory" of Green et al. 2 9 whic h was adopted for longitudinal bone growth by Isaksson et al. 3 0 . This theory suggests that GH stimulates the differentiation of mesenc hymal prec ursor c ells and then that loc ally produc ed growth GH and IGF-1 may also have synergistic effec ts regarding growth-promoting ac tivity in rats 3 2 .
Malpe et al. 3 3 published results indic ating that there are skeletal site-dependent differenc es in the produc tion of IGF. Skeletal site differenc es suggest that the regulation of bone metabolism may vary between different skeletal sites. Furthermore, there are a number of reports whic h show that the ac tion of GH on bone formation is site dependent. GH treatment results in a subperiosteal c ortic al bone formation, while no or minor effec t is found on c anc ellous bone 1 4 ,3 4 .
Growth H ormone and Interleukin-6
The multifunc tional c ytokine IL-6 is involved in bone remodeling. The osteosarc oma c ell line Saos-2 expressed very low levels of IL-6 3 5 , 3 6 , whereas the expression in the osteosarc oma c ell line MG 6 3 was similar to that found in human OBs. This finding indic ates that various c ell lines differ in their expression of c ytokines and that one c annot always extrapolate results from transformed c ell lines to normal OBs. The effec t of GH on the produc tion of IL-6 in human OBs has been investigated. GH inc reased IL-6 expression in a dose-and time-dependent manner in human OBs 3 5 . Similar results have previously been demonstrated in c hondroc ytes 3 6 . As the effec t of GH on IL-6 expression is major, one c ould assume that there is a physiologic al func tion for this regulation.
One may spec ulate that GH interac ts direc tly with the OBs to stimulate them to produc e IL-6 and, via an inc reased IL-6 produc tion, induc e OC differentiation whic h in turn results in inc reased bone resorption. An alternative effec t for IL-6 induc ed by GH, is suggested by studies demonstrating that IL-6 promotes the differentiation of OBs 3 7 and that IL-6 , in the presenc e of its soluble rec eptor, induc es the differentiation of unc ommitted embryonic fibroblasts towards c ells of the osteoblastic lineage 3 8 . Thus, these studies indic ate that IL-6 induc ed by GH c ould be of importanc e to bone formation.
Effects of Oestrogen on Growth H ormone Action and Growth H ormone Receptor Expression in H uman Osteoblast-like Cells
Oestrogen is important to maintaining a normal balanc e in bone remodeling. A severe dec rease of serum oestrogen levels after the c essation of ovarian func tion leads to postmenopausal osteoporosis. As GH is an important fac tor in the regulation of bone mass, it is of interest to study a possible interac tion between oestrogen and GH at the c ellular level in human OBs. Slootweg et al. 3 9 demonstrated the interac tion of oestrogen and GH with regard to their proliferative effec ts on OBs. Using c ertain c ulture c onditions, neither GH nor oestrogen stimulated c ell proliferation. Interestingly, when both hormones were administered together, an inc rease in proliferation was observed. The lac k of proliferative response to oestrogen alone in OBs c oheres with results from Ric kard et al. 4 Oestrogen was found to stimulate both GH-rec eptor mRNA levels, as well as GH binding. This inc rease in GH-rec eptor expression was found in both human OBs and in rat osteosarc oma c ells 3 9 . However, the dose-dependent effec ts of oestrogen on GH rec eptor expression are somewhat different between the human OB c ells and the UMR c ells.
This differenc e c ould be a result of spec ies differenc e and/ or that the two c ell types express different amounts or subtypes of the oestrogen rec eptor. The finding that oestrogen regulates GH rec eptor expression is supported by results from Gabrielsson et al. 4 3 , demonstrating that oestradiol upregulates GH rec eptor mRNA levels in rat liver. From the studies by Sandstedt et al. 4 4 it is c onc luded that elevated levels of GH inc rease the amount of vertebral as well as tibial bone in young female mic e and that intac t ovaries are a prerequisite for the stimulatory effec t of elevated GH levels. Furthermore, a c linic al study with ac romegalic women demonstrated that the anabolic effec t of GH on bone is more evident in the presenc e of oestrogens 4 5 . Together, these findings suggest that oestrogen modulates the GH response in vivo as well as in vitro. Some of the synergistic effec ts between GH and oestrogen may be explained by the fac t that oestrogen inc reases the number of GH rec eptors. One may spec ulate that a c ombined treatment with oestrogen and GH c ould be useful in the treatment of postmenopausal osteoporosis.
Effects of Glucocorticoids on H uman Osteoblast-like Cells
Cortisol is another hormone whic h is involved in bone remodeling and in the pathogenesis of osteoporosis 4 6 .
Cortisol exerts c omplex effec ts on bone tissue and on bone c ells. It is well known that high levels of c ortisol dec rease bone formation. Some studies indic ate that high levels of c ortisol also result in inc reased bone resorption.
It is important to distinguish between high ( pharmac ologic al) doses and low ( physiologic al) doses of c ortisol treatment. Low doses of c ortisol are mostly anabolic while high levels of c ortisol are c atabolic for bone tissue. High levels of gluc oc ortic oids result in dec reased c ollagen expression and in an inc rease in c ollagenase expression, whic h leads to the degradation of type I c ollagen 4 7 . Cheng et al. 4 8 have shown that gluc oc ortic oids stimulate the differentiation of human bone marrow stromal c ells into OB c ells. A positive effec t of physiologic al doses of gluc oc ortic oids is that they promote a more differentiated OB phenotype 4 9 . We have shown that a low dose of hydroc ortisone inc reases c ell proliferation and ALP ac tivity in human OBs 1 5 . This inc rease in c ell proliferation is similar to what Jonsson et al. 5 0 have shown for short-term treatment with low dose of gluc oc ortic oids. They also found that gluc oc ortic oids stimulation resulted in a biphasic effec t on proliferation, where a more prolonged gluc oc ortic oids period with high doses of gluc oc ortic oids were found to inhibit proliferation, reflec ting the c omplex mec hanism of ac tion for gluc oc ortic oids on bone c ells.
However, most studies demonstrate that prolonged treatment with high levels of gluc oc ortic oids is c atabolic for OBs.
The effec t of c ortisol on GH rec eptor expression has been studied by us in human OBs. Unexpec tedly, it was found that high levels of c ortisol inc reased GH rec eptor expression. Both GH-rec eptor mRNA levels and GH-binding were inc reased by high doses of c ortisol5 1 . One might have assumed that c ortisol would have dec reased GH rec eptor expression and, thereby, exerted a negative effec t on bone formation. However, these findings are similar to in vivo results in whic h gluc oc ortic oids inc reased GH-rec eptor mRNA levels in the liver and growth plate of rabbits 5 2 and in rat osteosarc oma c ells where gluc oc ortic oids inc reased GH binding 5 3 . Interestingly, Salles et al. 5 3 found that the GH rec eptor expression was enhanc ed by gluc oc ortic oids but the stimulatory effec t of GH on the proliferation of rat osteosarc oma c ells was partially bloc ked by a high dose of dexamethasone. These findings suggest that gluc oc ortic oids bloc k the GH effec t at a post-rec eptor level. Future studies will determine whether or not high levels of gluc oc ortic oids bloc k the GH-response at a postrec eptor level in human OBs.
Another mec hanism by whic h c ortisol regulates bone metabolism may be via a regulation of IGF expression. IGFs exert anabolic effec ts on OBs Further evidenc e that dec reased IGF-1 expression maybe important to a gluc oc ortic oid-induc ed dec rease in bone formation, is a study by Jonsson et al. 5 5 . The study demonstrates that a high dose of hydroc ortisone inhibits the release of c arboxyterminal propeptide of type I c ollagen into the c ulture medium of human OBs. The addition of IGF-1 normalized the release of c arboxyterminal propeptide of type I c ollagen from the hydroc ortisone inc ubated human OBs. This finding indic ates that IGF-1 has the c apac ity to reverse the negative effec ts of c ortisol on bone formation. In c onc lusion, in vitro data indic ate that IGF-1 may be a potential anabolic substanc e for the treatment of gluc oc ortic oids-induc ed osteoporosis.
To further investigate the effec ts of gluc oc ortic oids on human OBs, the interac tion between c ortisol and IL-1 and IL-6 , two c ytokines that are involved in bone remodeling, has been studied. We demonstrated that the expression of these two interleukins is dec reased by high doses of c ortisol 5 6 . Similar results have earlier been presented in studies using mouse OBs 5 7 . Furthermore, dexamethasone inhibited the release of IL-6 in human bone marrow stromal osteoprogenitor c ells 5 8 . The observations that c ortisol dec reases IL-6 and IL-1 b expression in OBs are somewhat surprising, as IL-6 and IL-1 , as well as c ortisol, have been regarded as fac tors whic h promote bone resorption. Thus, c ortisol-induc ed bone resorption c annot be explained by a c ortisol-induc ed dec rease of IL-6 and IL-1 produc tion in OBs. However, some studies indic ate that IL-6 and IL-1 may have a func tion as positive modulators of bone formation. The finding that c ortisol reduc es the produc tion of IL-6 and IL-1 in human OBs may also be a part of a generally applic able biologic al feed-bac k mec hanism for regulating the produc tion of c ytokines and not a major determinant for c ortisolinduc ed osteoporosis.
In c onc lusion, the in vitro model by using primary isolated human osteoblast-like c ells, c ontributes to inc reasing knowledge of basal mec hanisms in human bone physiology. The human osteoblast is a c ell whic h is highly affec ted by different hormones, c ytokines and growth fac tors. The regulation of all these substanc es have to be further studied as well as all the sec rets of the osteoblasts. The new information may hopefully result in development of new treatment strategies for patients with osteoporosis, growth disorders and metabolic bone diseases. 
